Vytorin does not appear to be unsafe – American Heart Association

Schering-Plough Corp and Merck & Co are defending their shared cholesterol treatments, Vytorin and Zetia, in advertisements in The New York Times after a failed study generated negative publicity. – Merck/Schering-Plough Pharmaceuticals released results from the ENHANCE trial, which found that the ezetimibe/simvastatin (Zetia/Zocor) combination drug known as Vytorin was no more effective in reducing artery plaque build-up than simvastatin (Zocor) alone. There were no statistically significant differences in the safety of the drugs, which are used to lower cholesterol.

Gene changes may lead to hardening of arteries, atherosclerosis

A genetic mutation expands lesions in the aorta and promotes coronary atherosclerosis, more commonly known as hardening of the arteries, according to a study by Yale School of Medicine in Cell Metabolism. – Researchers revealed that changes in gene may lead to hardening of the arteries and expands lesions in the aorta and promotes coronary atherosclerosis. The study was done by researchers from Yale School of Medicine and published in Cell Metabolism.

Immune system responsible for increased inflammation in diabetes patients

Immune system found responsible for increased inflammation in diabetes patients. With good diabetes control, this inflammation may be reduced, possibly resulting in a reduction of cardiovascular disease as well.
– Researchers at UC Davis Health System have discovered a novel pathway that results in increased inflammation of blood vessels in patients with type 1 diabetes. Their findings suggest that, with good diabetes control, this inflammation may be reduced, possibly resulting in a reduction of cardiovascular disease as well.

Health Newstrack